

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

ARISTOS-COFUND POSTDOCTORAL PROGRAMME IN BIOMEDICINE AND HEALTH SCIENCES (MSCA-COFUND)

CALL 2024 FOR CANDIDATES FOR POSTDOCTORAL POSITION

Provisional list of evaluation scores

Following the evaluation by the external peer-reviewers, on February 20th, 2025, the Recruitment Committee, in charge of approving the provisional shortlisted projects (score over 70% threshold) for the 2024 call for the ARISTOS Programme, has agreed:

1.- Approve the **provisional list of evaluation scores**. Projects with **score over 70% threshold, will be called to an interview**.

The list of evaluation scores (Annex I) is published in this document. Each candidate will also be informed by email and through the website personal area.

Each proposal was evaluated by three external referees who scored and ranked applications according to the ARISTOS Evaluation Criteria. Priority in case of proposals with the same score (ex aequo) was considered as defined in the table.

EVALUATION CRITERIA		
<p>EXCELLENCE</p> <p>Quality, creativity, innovative aspects and credibility of the research objectives (including multidisciplinary aspects benefiting from CIBER interdisciplinarity) Intersectoral aspects of the research objective (academic, industry, societal) specific to the aims of the Program. Suitability of the selected seconding company. Quality of the academic track record of the applicant relative to the research proposed (e.g. patents, publications, research stays, projects) Compliance of the proposal with the Open Science principles.</p> <p>Weight: 40% (priority 1)</p>	<p>IMPACT</p> <p>Consistency of the research project with the hosting research group. Effectiveness of the proposed communication, exploitation and dissemination plan relative to the research field. Fellows' potential to establish a leadership role in the proposal field, apt to their experience level, in Spain/internationally and in academia/ industry. Potential for increased impact of research via industry/clinical collaboration.</p> <p>Weight: 35% (priority 2)</p>	<p>IMPLEMENTATION</p> <p>Overall coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks and resources, and the contingency plan. Opportunity to enhance research, via appropriate international collaboration with relevant industry & clinical sectors; potential development of proof of concepts. Match of the host group's infrastructure with the project scope</p> <p>Weight: 25% (priority 3)</p>
AN OVERALL THRESHOLD OF 70% WILL BE APPLIED TO THE TOTAL WEIGHTED SCORE		



Co-funded by
the European Union

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

DEADLINE FOR REQUESTS FOR REDRESS:

Candidates have the opportunity to submit an appeal against the score of his/her proposal if they believe the score was based on an error in the evaluation procedure. See ARISTOS Redress Template among the templates of the Download area of ARISTOS website <https://postdoc-aristos.com/HowToApply>

All requests for redress have to be uploaded through the personal area website. The redress will only evaluate the evaluation procedure and perceived incorrect application of the eligibility criteria and not the scientific judgement of the peer reviewers.

Redress deadline: 07/03/2025, 12pm Madrid, Spain

IMPORTANT INFORMATION:

Proposals (with score over 70% threshold) will now be screened by the ARISTOS Ethics Committee to check if they comply with the ethical requirements of the call. Ethics review will be performed on the basis of information available in the proposal.

An individual ethics assessment report will be emitted by the Ethics Committee and will be available through the website Personal Area at the end of the evaluation process. **Proposals that raise ethics concerns will be flagged for further ethics clearance and if some aspects are incomplete, clarification will be sought. In this sense, research proposals ignoring ethic concerns will be rejected from the Program.** Selected Fellows will be required to respond to the Committee's assessment after the acceptance of their project but before the start of their contract.

- ✓ Interviews will be held **in English** and will be scheduled **via videoconference**
- ✓ Candidates will be judged by the interview panel on their **overall merit as researchers, their creativity and level of independence.**
- ✓ All interviews will last **45 minutes (maximum)**, starting with a **10 minutes presentation of the project, followed by a scientific discussion, for the overall assessment of the nonscientific personal skills.** The ethical issues and how the proposed project adhere to open science procedures may be addressed during the interviews.

Criteria to be valued during the interview are as follows:

Interview award criteria	Weight
Capacity to defend the project	40
Communication and presentation skills	30
Motivation and enthusiasm for interdisciplinary research	15
Attitude, autonomous thinking, teamwork capacity and leading abilities	15

Each applicant's **final mark** will be based on the evaluation of the **submitted proposal (70%) and the interview assessment (30%)**. Candidates should again **exceed a threshold of 70%** in the total score **to be appointed. 3.** The shortlist will become public on the website (April 2025). Admitted Fellows will then be contacted for the initiation of the hiring process. All contracts are estimated to initiate before the end of May 2025. Appointed researchers will be requested to validate their PhD degree

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

ANNEX I: PROVISIONAL LIST OF EVALUATION SCORES FOR THE 2024 CALL OF THE ARISTOS PROGRAMME

Candidate's Reference	Name	Excellence Criteria (40%)	Impact Criteria (35%)	Implementation Criteria (25%)	Final Score/5	FINAL SCORE %	Area	To be called to an interview
24/APL30164	S*** R***	4,67	4,50	4,50	4,57	91,33	CiberBBN	YES
24/APL30135	S*** Ç***	4,17	3,50	3,67	3,81	76,17	CiberBBN	YES
24/APL30136	L*** B*** G***	4,00	3,67	3,50	3,76	75,17	CiberBBN	YES
24/APL30157	L*** V***	3,50	3,17	3,00	3,26	65,17	CiberBBN	NO
24/APL30149	P*** J*** J***	2,50	2,00	2,50	2,33	46,50	CiberBBN	NO

Candidate's Reference	Name	Excellence Criteria (40%)	Impact Criteria (35%)	Implementation Criteria (25%)	Final Score/5	FINAL SCORE %	Area	To be called to an interview
24/APL30124	O*** R*** G***	4,33	4,67	4,50	4,49	89,83	CiberCV	YES

Candidate's Reference	Name	Excellence Criteria (40%)	Impact Criteria (35%)	Implementation Criteria (25%)	Final Score/5	FINAL SCORE %	Area	To be called to an interview
24/APL30148	A*** A*** K***	2,83	3,67	3,50	3,29	65,83	CiberDEM	NO

Candidate's Reference	Name	Excellence Criteria (40%)	Impact Criteria (35%)	Implementation Criteria (25%)	Final Score/5	FINAL SCORE %	Area	To be called to an interview
24/APL30140	L*** C*** B***	4,50	4,75	3,75	4,40	88,00	CiberEHD	YES

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

Candidate's Reference	Name	Excellence Criteria (40%)	Impact Criteria (35%)	Implementation Criteria (25%)	Final Score/5	FINAL SCORE %	Area	To be called to an interview
24/APL30155	A*** T*** G***	4,50	4,67	4,33	4,52	90,33	CiberER	YES
24/APL30127	M*** M***-L*** G***	4,50	4,50	4,33	4,46	89,17	CiberER	YES
24/APL30152	N*** S*** B***	3,33	3,67	3,50	3,49	69,83	CiberER	NO

Candidate's Reference	Name	Excellence Criteria (40%)	Impact Criteria (35%)	Implementation Criteria (25%)	Final Score/5	FINAL SCORE %	Area	To be called to an interview
24/APL30144	R*** V*** C***	4,50	4,50	4,17	4,42	88,33	CiberESP	YES
24/APL30128	F*** I***	4,33	4,00	3,83	4,09	81,83	CiberESP	YES
24/APL30161	J*** A*** d*** I*** T***	4,33	3,83	4,00	4,08	81,50	CiberESP	YES
24/APL30126	V*** L***	4,17	4,00	3,33	3,90	78,00	CiberESP	YES
24/APL30143	M*** d*** M*** R***	3,67	3,67	4,00	3,75	75,00	CiberESP	YES
24/APL30153	L*** M*** R*** D***	3,17	3,17	3,67	3,29	65,83	CiberESP	NO
24/APL30166	A*** A***	3,17	3,00	2,83	3,03	60,50	CiberESP	NO
24/APL30147	M*** H***	2,00	2,17	1,83	2,02	40,33	CiberESP	NO

Candidate's Reference	Name	Excellence Criteria (40%)	Impact Criteria (35%)	Implementation Criteria (25%)	Final Score/5	FINAL SCORE %	Area	To be called to an interview
24/APL30139	I*** S***-G*** S***	4,83	4,50	4,67	4,68	93,50	CiberNED	YES
24/APL30133	M*** C*** F***	4,33	4,33	4,67	4,42	88,33	CiberNED	YES
24/APL30160	M*** L*** M***	4,50	4,17	4,50	4,38	87,67	CiberNED	YES
24/APL30163	E*** F*** S***	4,33	4,33	4,50	4,38	87,50	CiberNED	YES
24/APL30132	C*** A*** R***	4,00	4,33	4,33	4,20	84,00	CiberNED	YES
24/APL30167	M*** D***	3,83	3,83	3,83	3,83	76,67	CiberNED	YES
24/APL30158	P*** M*** G***	3,83	3,67	4,00	3,82	76,33	CiberNED	YES
24/APL30168	H*** T*** T*** M***	3,83	3,83	3,67	3,79	75,83	CiberNED	YES
24/APL30159	E*** d*** C*** P*** C***	3,50	3,67	3,67	3,60	72,00	CiberNED	YES

ARISTOS has received funding from the European Union's Horizon Europe research and innovation programme under the Marie Skłodowska-Curie grant agreement No 101081334

Candidate's Reference	Name	Excellence Criteria (40%)	Impact Criteria (35%)	Implementation Criteria (25%)	Final Score/5	FINAL SCORE %	Area	To be called to an interview
24/APL30130	M*** C***	4,33	3,67	3,50	3,89	77,83	CiberOBN	YES
24/APL30134	G*** M***M***	3,50	3,67	3,17	3,48	69,50	CiberOBN	NO
24/APL30162	A*** D*** O*** R***	2,50	2,33	2,17	2,36	47,17	CiberOBN	NO

Candidate's Reference	Name	Excellence Criteria (40%)	Impact Criteria (35%)	Implementation Criteria (25%)	Final Score/5	FINAL SCORE %	Area	To be called to an interview
24/APL30125	J*** K***	4,50	4,50	4,00	4,38	87,50	CiberONC	YES
24/APL30169	I*** S*** d***S*** M*** F***	4,50	3,83	4,17	4,18	83,67	CiberONC	YES
24/APL30154	B*** M*** C***	3,67	4,33	4,33	4,07	81,33	CiberONC	YES
24/APL30138	M*** d*** R*** C*** G***	3,33	3,50	3,67	3,48	69,50	CiberONC	NO
24/APL30123	C*** B*** S***	3,33	3,00	3,67	3,30	66,00	CiberONC	NO